Contact us
Contact us


by Feldan Therapeutics on Oct 3,2023

Québec City, Canada, October 3, 2023 - Feldan Therapeutics (“Feldan” or the “Company”), a biopharmaceutical company specializing in the development of treatments based on the intracellular delivery of therapeutics, is pleased to announce the appointment of Dr. David J. Mazzo as Chairman of the Board. Dr. Mazzo has been serving as an independent director on the Company's board since January 2021 and his nomination follows the Company’s recent successful initial closing of a Series B financing.

"We are delighted to welcome David as our Chairman. His extensive pharmaceutical development knowledge, strategic insight and leadership have been highly valuable since he joined our Board in 2021 and will be instrumental in driving our efforts as Feldan transitions to a clinical development stage company with the initiation of our First-in-Human trial of FLD-103 in early 2024," said François-Thomas Michaud, Ph.D., co-founder and Chief Executive Officer of Feldan. "David is deeply committed to our mission of pioneering intracellular delivery and making a profound impact on healthcare and the lives of patients. Our team is grateful for his contribution at such a pivotal moment in our journey and looks forward to achieving great success under his visionary approach."

“I am both honored and delighted to assume the role of Chairman of the Board at Feldan.” said Dr. Mazzo “I am continually impressed by the extreme quality of science and strategic thinking exhibited by Feldan’s team of talented and committed people and am excited to be part of their quest to bring truly innovative therapies to market in areas of profound unmet medical need.”

David J. Mazzo, Ph.D., is a pharmaceutical executive and strategic leader with an impressive track record of 40 years of experience in the development and launch of drug products for both large and emerging pharmaceutical companies in the U.S., Canada, Europe and Japan. He currently serves as President and Chief Executive Officer of Lisata Therapeutics, Inc.

Throughout his career, Dr. Mazzo has held leadership positions in research and development at renowned multinational companies such as Hoechst Marion Roussel and Schering-Plough. He has also successfully led emerging pharmaceutical companies as CEO, including Chugai USA, Aeterna Zentaris and Regado Biosciences. His talents in strategy, science and regulatory affairs have led to numerous successes in global product development, registration and launch. In addition to his executive roles, Dr. Mazzo has demonstrated his expertise as an experienced director of both public and private companies. He has shared his insights with the board of every company he has overseen as a CEO. In addition, he served on the Board of Essex Chimie AG (EU subsidiary of Schering-Plough), Avanir Pharmaceuticals, EyePoint Pharmaceuticals (as Chairman of the Board), and Seneca Biopharma.  He currently serves as Chairman of the Board of Visioneering Technologies, Inc. (ASX:VTI).

Dr. Mazzo holds a Ph.D. in Analytical Chemistry and an M.S. in Chemistry from the University of Massachusetts (Amherst). His academic background also includes dual degrees, a B.S. in Chemistry and a B.A. in Honors (Interdisciplinary Humanities) from Villanova University, as well as a Research Fellowship at the École Polytechnique Fédérale de Lausanne in Switzerland.

About Feldan:
Located in Quebec City, Canada, Feldan is a biopharmaceutical company pioneering the development of treatments based on the intracellular delivery of therapeutics. Feldan has designed the Feldan Shuttle, a proprietary, peptide-based technology that enables safe and efficient delivery of various compounds inside cells. This technology unlocks the development of a new generation of therapies by giving access to intracellular targets beyond the reach of existing drugs. Feldan’s pipeline currently focuses on diseases affecting the skin and lungs.

Feldan’s operational and strategic focus is on the completion of clinical phase I/II trials of intralesional FLD-103 to treat basal cell carcinomas (BCC). BCC, the most common skin cancer and most frequent form of all cancers, affects 3.6 million people in the US and Canada each year and results in the development of tumors mainly in sun-exposed skin areas such as the face, neck and scalp. Patients affected by BCC mostly rely on surgery for removal of these tumors, an effective yet invasive and disfiguring procedure leaving patients to deal with scarring and, in some instances, a long recovery time. The Company is also working on advancing its pulmonary delivery program towards clinical development and further leveraging its intracellular delivery technology to offer life-changing therapeutics to patients.

For more information: